NTLA (Intellia Therapeutics) Cyclically Adjusted Book per Share: $9.62 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTLA Intellia Therapeutics Inc NTLA
70 GF Score
Price $11.91
GF Value $13.80
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted Book per Share?

Intellia Therapeutics NTLA +0.76% 70 Cyclically Adjusted Book per Share is $9.62 as of Jun. 2026. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $13.80 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Intellia Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was $5.197. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.62 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Intellia Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-16), Intellia Therapeutics's current stock price is $11.91. Intellia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $9.62. Intellia Therapeutics's Cyclically Adjusted PB Ratio of today is 1.24.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intellia Therapeutics was 2.81. The lowest was 0.73. And the median was 1.30.


Intellia Therapeutics  (NAS:NTLA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intellia Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.91/9.62
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intellia Therapeutics was 2.81. The lowest was 0.73. And the median was 1.30.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Intellia Therapeutics Cyclically Adjusted Book per Share Related Terms


Intellia Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted Book per Share Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.03 9.26

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.12 9.12 9.26 9.60 9.62

NTLA vs SEPN, AVBP, VIR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted PB Ratio falls into.


NTLA
70GF Score
Intellia Therapeutics Inc NTLA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intellia Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.197/333.9520*333.9520
=5.197

Current CPI (Jun. 2026) = 333.9520.

Intellia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.060 241.428 8.382
201612 5.826 241.432 8.059
201703 5.548 243.801 7.599
201706 5.201 244.955 7.091
201709 4.873 246.819 6.593
201712 7.092 246.524 9.607
201803 6.857 249.554 9.176
201806 6.468 251.989 8.572
201809 6.070 252.439 8.030
201812 6.379 251.233 8.479
201903 5.812 254.202 7.635
201906 5.802 256.143 7.564
201909 5.640 256.759 7.336
201912 5.376 256.974 6.986
202003 4.896 258.115 6.334
202006 5.987 257.797 7.756
202009 5.607 260.280 7.194
202012 7.958 260.474 10.203
202103 8.041 264.877 10.138
202106 7.241 271.696 8.900
202109 14.892 274.310 18.130
202112 13.966 278.802 16.729
202203 12.612 287.504 14.650
202206 11.586 296.311 13.058
202209 10.771 296.808 12.119
202212 14.185 296.797 15.961
202303 13.518 301.836 14.956
202306 12.506 305.109 13.688
202309 11.644 307.789 12.634
202312 11.293 306.746 12.295
202403 10.756 312.332 11.501
202406 9.880 314.175 10.502
202409 9.456 315.301 10.015
202412 8.546 315.605 9.043
202503 7.533 319.799 7.866
202506 6.791 322.561 7.031
202509 6.464 324.800 6.646
202512 5.772 324.054 5.948
202603 5.155 330.213 5.213
202606 5.197 333.952 5.197

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $9.62 mean?
Intellia Therapeutics (NTLA) has a Cyclically Adjusted Book per Share of $9.62 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Cyclically Adjusted Book per Share too high?
Intellia Therapeutics' current Cyclically Adjusted Book per Share is $9.62. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Cyclically Adjusted Book per Share compare to SEPN and AVBP?
Intellia Therapeutics' Cyclically Adjusted Book per Share of $9.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Cyclically Adjusted Book per Share is $9.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.80, compared to a current price of $11.91 — trading 13.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is $9.62. Intellia Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Cyclically Adjusted Book per Share is $9.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $11.91 is trading 13.7% below its estimated GF Value™ of $13.80. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Cyclically Adjusted Book per Share: $9.62
  • GF Value™: $13.80 vs. price of $11.91 (13.7% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score

Get the complete analysis for NTLA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.91
Price
$13.80
GF Value